Following the COURAGE trial, the results from the National Institutes of Health-National Heart, Lung and Blood Institute- (NIH-NHLBI-) sponsored BARI 2D
(Bypass Angioplasty Revascularization Investigation 2 Diabetes) study were reported .
To examine the possible relationship between elevated troponin T and adverse CV outcomes in patients who had both stable ischemic heart disease and diabetes, the investigators performed a post hoc analysis of data gathered in the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D
) clinical trial, which compared outcomes between patients who underwent preventive percutaneous coronary intervention or coronary artery bypass grafting plus intensive medical therapy against those who received intensive medical therapy alone.
[sup] Furthermore, the BARI 2D
trial showed that elevated baseline plasma Fg level portends poor clinical outcomes with diabetic vasculopathy [sup] and provides prognostic influence in unstable coronary disease.
CHICAGO -- Abnormal levels of high-sensitivity cardiac troponin T are present in 40% of type 2 diabetic patients with stable ischemic heart disease, and they do not bode well, according to a secondary analysis of the BARI 2D
To address the cardiovascular disease, patients in BARI 2D
were randomly assigned to receive intensive medical therapy plus revascularization treatment (such as angioplasty or bypass surgery) or intensive medical therapy alone (with the possibility of revascularization treatment later if their symptoms did not improve).
Diyabetik CDH'da koroner baypas ve ISS etkinligini karsilastiran randomize kontrollu diger iki buyuk calisma FREEDOM ve BARI 2D
(18, 19) calismalari da halen devam etmektedir.
An interim analysis of the Bypass Angioplasty Revascularization Investigation in Type 2 Diabetes (BARI 2D
) trial funded by the National Institutes of Health also uncovered no signal for harm by rosiglitazone that would compel the investigators to discontinue the study.
The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D
) clinical trial compared cardiovascular and diabetes treatment strategies with respect to mortality and cardiovascular events in patients with T2DM and stable CAD [3, 4].
The study, an analysis of data from the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D
) trial, was published online July 15 (doi: 10.1161/CIRCULATIONAHA.112.000678).
ORLANDO - Virtually no patients with type 2 diabetes and documented coronary artery disease and coronary ischemia benefit from immediate coronary revascularization, as long as they receive intensive medical management, based on the outcomes of more than 1,000 patients randomized to the deferred revascularization arm of the BARI 2D
Rosiglitazone therapy n BARI 2D
demonstrates rather reassuring efficacy and safety data.
(13.) Pop-Busui R, Lu J, Brooks MM, et al; the BARI 2D